These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30133803)

  • 21. [The role of Sabin inactivated poliovirus vaccine in the final phase of global polio eradication].
    Dong SZ; Zhu WB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2016 Dec; 50(12):1032-1035. PubMed ID: 28057104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.
    Chu K; Ying Z; Wang L; Hu Y; Xia J; Chen L; Wang J; Li C; Zhang Q; Gao Q; Hu Y
    Vaccine; 2018 Oct; 36(45):6782-6789. PubMed ID: 30249424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity of Two Different Sequential Schedules of Inactivated Polio Vaccine Followed by Oral Polio Vaccine Versus Oral Polio Vaccine Alone in Healthy Infants in China.
    Li RC; Li CG; Wang HB; Luo HM; Li YP; Wang JF; Ying ZF; Yu WZ; Shu JD; Wen N; Vidor E
    J Pediatric Infect Dis Soc; 2016 Sep; 5(3):287-96. PubMed ID: 26407255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains.
    Verdijk P; Rots NY; Bakker WA
    Expert Rev Vaccines; 2011 May; 10(5):635-44. PubMed ID: 21604984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial.
    Liao G; Li R; Li C; Sun M; Li Y; Chu J; Jiang S; Li Q
    J Infect Dis; 2012 Jan; 205(2):237-43. PubMed ID: 22158682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
    Sawyer LA; McInnis J; Albrecht P
    Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
    Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
    Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characteristics of the immune response to poliovirus virion polypeptides after immunization with live or inactivated polio vaccines.
    Zhaori G; Sun M; Ogra PL
    J Infect Dis; 1988 Jul; 158(1):160-5. PubMed ID: 2839578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
    Yang C; Shi H; Zhou J; Liang Y; Xu H
    Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trypsin diminishes the rat potency of polio serotype 3.
    ten Have R; Westdijk J; Levels LM; Koedam P; de Haan A; Hamzink MR; Metz B; Kersten GF
    Biologicals; 2015 Nov; 43(6):474-8. PubMed ID: 26321654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An adjuvant compound that enhances immunogenicity at fractional doses of the Sabin-inactivated poliovirus vaccine (sIPV) with a long duration of protection in a rat model.
    Song S; Liu Z; Zhou J; Cai W; Yang H; Ma L; Gao J; Li W; Liao G
    J Med Virol; 2019 Jan; 91(1):14-21. PubMed ID: 30168587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses.
    Muller DA; Pearson FE; Fernando GJ; Agyei-Yeboah C; Owens NS; Corrie SR; Crichton ML; Wei JC; Weldon WC; Oberste MS; Young PR; Kendall MA
    Sci Rep; 2016 Feb; 6():22094. PubMed ID: 26911254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity of trypsin treated type 2 and type 3 poliovirus in rats.
    Kersten GF; Lantinga M; Hazendonk T; Beuvery EC
    Biologicals; 1995 Jun; 23(2):179-83. PubMed ID: 7546661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine-only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants.
    Brickley EB; Wieland-Alter W; Connor RI; Ackerman ME; Boesch AW; Arita M; Weldon WC; O'Ryan MG; Bandyopadhyay AS; Wright PF
    Clin Infect Dis; 2018 Oct; 67(suppl_1):S42-S50. PubMed ID: 30376086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of 2-phenoxyethanol on potency of Sabin inactivated poliomyelitis vaccine and its safety].
    Bian CX; Jiang SD; Yang JY; Sun MB; Xie MX; Zhang XW; Liao GY; Li WD
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):44-6. PubMed ID: 17429533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune response to an intercalated enhanced inactivated polio vaccine/oral polio vaccine programme in Israel: impact on the control of poliomyelitis.
    Swartz TA; Handsher R; Manor Y; Stoeckel P; Barkay A; Mendelson E; Leventhal A
    Vaccine; 1998 Dec; 16(20):2090-5. PubMed ID: 9796069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antigenic characterization of a formalin-inactivated poliovirus vaccine derived from live-attenuated Sabin strains.
    Tano Y; Shimizu H; Martin J; Nishimura Y; Simizu B; Miyamura T
    Vaccine; 2007 Oct; 25(41):7041-6. PubMed ID: 17825459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Enhancing the immunogenicity of inactivated polio vaccines with chitosan used as an adjuvant].
    Gendon IuZ; Markushin SG; Akopova II; Krivtsov GG; Akhmatova NK; Koptiaeva IB; Vasil'ev IuM
    Vopr Virusol; 2011; 56(6):28-32. PubMed ID: 22359946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 3 Trial of a Sabin Strain-Based Inactivated Poliovirus Vaccine.
    Liao G; Li R; Li C; Sun M; Jiang S; Li Y; Mo Z; Xia J; Xie Z; Che Y; Yang J; Yin Z; Wang J; Chu J; Cai W; Zhou J; Wang J; Li Q
    J Infect Dis; 2016 Dec; 214(11):1728-1734. PubMed ID: 27658691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. sIPV process development for costs reduction.
    Thomassen YE; Bakker WA
    Vaccine; 2015 Aug; 33(35):4307-12. PubMed ID: 25858858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.